Related Experiment Video
Updated: Oct 27, 2025
08:02
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
9.9K
Using biomarkers to adjust corticosteroid dose in patients with severe asthma
1Dept of Respiratory Medicine, Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, UK.
Breathe (Sheffield, England)
|July 23, 2021
Summary
Biomarkers can help reduce inhaled corticosteroid use in severe asthma when treatment guidelines are followed. T2-low asthma phenotypes are less prevalent than previously estimated.
Area of Science:
- Pulmonology
- Allergy and Immunology
- Biomarker Research
Background:
- Severe asthma management often involves high-dose inhaled corticosteroids (ICS).
- Identifying asthma phenotypes is crucial for personalized treatment strategies.
- The prevalence of T2-low asthma has been debated.
Purpose of the Study:
- To evaluate the utility of biomarkers in guiding ICS reduction in severe asthma.
- To determine the actual prevalence of T2-low asthma.
- To assess adherence to treatment recommendations for ICS reduction.
Main Methods:
- Analysis of patient data from a severe asthma cohort.
- Utilized specific biomarkers to stratify patients.
- Monitored adherence to physician-prescribed treatment plans.
Main Results:
- Biomarker-guided ICS reduction was effective when treatment advice was followed.
- The prevalence of T2-low asthma was found to be lower than anticipated.
- Adherence to treatment significantly impacted the success of ICS reduction.
Conclusions:
- Biomarker-driven therapeutic adjustments can optimize inhaled corticosteroid (ICS) burden in severe asthma.
- T2-low asthma is a less frequent phenotype than previously considered.
- Treatment adherence is a critical factor for successful biomarker-guided asthma management.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
613
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
613
01:26COPD: Management Using Bronchodilators and Corticosteroids
498
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
498
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
251
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
787
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
787
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
848
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
848
01:23Inhaled Medications
490
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
490